# A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

> **NCT05600777** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bellus Health Inc. - a GSK company** · enrollment: 975 (estimated)

## Conditions studied

- Cough
- Refractory Chronic Cough

## Interventions

- **DRUG:** BLU-5937
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05600777
- **Lead sponsor:** Bellus Health Inc. - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-05
- **Primary completion:** 2026-06-11
- **Final completion:** 2027-03-17
- **Target enrollment:** 975 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05600777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05600777, "A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT05600777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*